

# ACT No. 125

2023 Regular Session

HOUSE BILL NO. 403

BY REPRESENTATIVE BROWN

1 AN ACT

2 To amend and reenact R.S. 22:1053(A)(2), relative to coverage of step therapy or fail first  
3 protocols; to authorize substitution of biosimilar biological products designated by  
4 the federal Food and Drug Administration; and to provide for related matters.

5 Be it enacted by the Legislature of Louisiana:

6 Section 1. R.S. 22:1053(A)(2) is hereby amended and reenacted to read as follows:

7 §1053. Requirement for coverage of step therapy or fail first protocols

8 A.

9 \* \* \*

10 (2) The provisions of this Section shall not be construed to prohibit the  
11 substitution of an AB-rated generic equivalent, biosimilar, or interchangeable  
12 biological product as designated by the federal Food and Drug Administration.

13 \* \* \*

\_\_\_\_\_  
SPEAKER OF THE HOUSE OF REPRESENTATIVES

\_\_\_\_\_  
PRESIDENT OF THE SENATE

\_\_\_\_\_  
GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: \_\_\_\_\_